关键词: 肝动脉灌注化疗, 肝细胞癌, 早期活动, 不良事件

Abstract: Objective:To investigate the safety and feasibility of relieving bed restriction during hepatic arterial infusion chemotherapy (HAIC).
Method:Select patients with primary liver cancer in line with the enrollment criteria, divided them into the experimental group (n=50) and control group (n=20) according to the order of admission date, the experimental group built FOLFOX-HAIC for relieving bed restriction activity program based on enhanced recovery after surgery (ERAS) concept, the patients in this group could get out of bed with an arterial catheter 6 hours after femoral artery catheterization; The patients in the control group were strictly confined to bed after catheterization until drug infusion, and got out of bed after drug infusion and femoral arterial catheter extraction. The complications of the two groups were observed. The pain level was assessed using the numerical rating scale (NRS). The Improved Changhai pain rating scale was used to evaluate patients' pain degree, and the daily life of patients in the two groups was evaluated by the Kolcaba general comfort questionnaire (GCQ) and Barthel index (BI). The incidence of postoperative complications and adverse events were recorded.
Result:Totally 70 cases of primary liver cancer treated with FOLFOX-HAIC were successfully completed FOLFOX-HAIC. The results showed that there were no adverse events such as falls and deaths in both groups after treatment. There was no statistically significant difference (P>0.05) in the femoral artery puncture point bleeding and subcutaneous hematoma. There was 1 case of external interface rupture in each group during the treatment period (experimental group 1/50, 2.0%; control group 1/20, 5.0%; P>0.05), which may be related to the quality of microcatheter, after communicating with relevant departments to replace the catheter, this phenomenon did not occur again. There were statistically significant differences between the two groups in postoperative complications: limb numbness, lumbar acid, loss of appetite, constipation and sleep disorders (P<0.05). There were statistically significant differences in comfort status and self-care ability between the two groups during the period of perfusion chemotherapy (both P<0.001).
Conclusion:FOLFOX-HAIC for relieving bed restriction scheme can be tried clinically.

Key words: Hepatic arterial infusion chemotherapy, Hepatocellular carcinoma, Early activity, Adverse events